Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avastin Plus Rituximab in Relapsed/Refractory Aggressive B-Cell NHL
NCT00081861Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2004
- Primary completion
- Sep 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in B-cell non-Hodgkin lymphoma (B-NHL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Number of Participants With Response (Complete Response or Progressive Disease) at 8 weeks. Started Mar 2004; status: completed.
02
Drugs
bevacizumab
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT00081861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00081861.